Semiquantitative assessment of osteoblastic, osteolytic, and mixed lytic-sclerotic bone lesions on fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphy

Basit Öğe Kaydı
dc.authoridSarikaya, Ismet/0000-0002-1087-580X
dc.authoridGuray, Gurkan/0000-0003-1221-0841
dc.authorwosidSarikaya, Ismet/G-7881-2015
dc.contributor.authorGurkan, Guray
dc.contributor.authorSarikaya, Ismet
dc.contributor.authorSarikaya, Ali
dc.date.accessioned2024-06-12T10:54:58Z
dc.date.available2024-06-12T10:54:58Z
dc.date.issued2019
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBone scintigraphy is widely used to detect bone metastases, particularly osteoblastic ones, and F-18 fluorodeoxyglucose (FDG) positron emission tomography (PET) scan is useful in detecting lytic bone metastases. In routine studies, images are assessed visually. In this retrospective study, we aimed to assess the osteoblastic, osteolytic, and mixed lytic-sclerotic bone lesions semiquantitatively by measuring maximum standardized uptake value (SUVmax) on FDG PET/computed tomography (CT), maximum lesion to normal bone count ratio (ROImax) on bone scintigraphy, and Hounsfield unit (HU) on CT. Bone scintigraphy and FDG PET/CT images of 33 patients with various solid tumors were evaluated. Osteoblastic, osteolytic, and mixed lesions were identified on CT and SUVmax, ROImax, and HU values of these lesions were measured. Statistical analysis was performed to determine if there is a difference in SUVmax, ROImax, and HU values of osteoblastic, osteolytic, and mixed lesions and any correlation between these values. Patients had various solid tumors, mainly lung, breast, and prostate cancers. There were 145 bone lesions (22.8% osteoblastic, 53.1% osteolytic, and 24.1% mixed) on CT. Osteoblastic lesions had a significantly higher value of CT HU as compared to osteolytic and mixed lesions (P < 0.01). There was no significant difference in mean ROImaxand mean SUVmaxvalues of osteolytic and osteoblastic bone lesions. There was no correlation between SUVmaxand ROImax, SUVmaxand HU, and ROImaxand HU values in osteolytic, osteoblastic, and mixed lesions (P > 0.05). Not finding a significant difference in SUVmaxand ROImaxvalues of osteoblastic, osteolytic, and mixed lesions and also lack of correlation between SUVmax, ROImax, and HU values could be due to treatment status of the bone lesions, size of the lesion, nonmetastatic lesions, erroneous measurement of SUVmaxand ROImax, or varying metabolism in bone metastases originating from various malignancies.en_US
dc.identifier.doi10.4103/wjnm.WJNM_31_18
dc.identifier.endpage136en_US
dc.identifier.issn1450-1147
dc.identifier.issn1607-3312
dc.identifier.issue2en_US
dc.identifier.pmid31040743en_US
dc.identifier.startpage132en_US
dc.identifier.urihttps://doi.org/10.4103/wjnm.WJNM_31_18
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19245
dc.identifier.volume18en_US
dc.identifier.wosWOS:000672644400003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofWorld Journal Of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBone Scintigraphyen_US
dc.subjectFluorodeoxyglucose Positron Emission Tomographyen_US
dc.subjectComputed Tomographyen_US
dc.subjectOsteoblasticen_US
dc.subjectOsteolyticen_US
dc.subjectSemiquantitativeen_US
dc.titleSemiquantitative assessment of osteoblastic, osteolytic, and mixed lytic-sclerotic bone lesions on fluorodeoxyglucose positron emission tomography/computed tomography and bone scintigraphyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu